Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Cancer
    June 2026
  1. LAWRENCE L
    No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity.
    Cancer. 2026;132:e70439.
    >> Share

    March 2026

  2. Correction to "Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele".
    Cancer. 2026;132:e70350.
    >> Share

  3. DESSINIOTI C, Stratigos A
    Neoadjuvant systemic immunotherapy for skin cancers.
    Cancer. 2026;132:e70354.
    >> Share

  4. FIELDS BC, Traweek RS, Jiang K, Witt RG, et al
    High dietary fiber is associated with improved outcomes in patients with melanoma and sarcoma treated with immunotherapy regardless of gut microbiome dysbiosis and social vulnerability.
    Cancer. 2026;132:e70335.
    >> Share

    February 2026
  5. ZAKHARIA Y, Kim D, Freesmeier M, Frees M, et al
    A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.
    Cancer. 2026;132:e70326.
    >> Share

  6. DILEO M, Oglesby S, Leung CH, Pauken KE, et al
    Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.
    Cancer. 2026;132:e70262.
    >> Share

  7. LAWRENCE L
    Nine-year data show sustained benefit of nivolumab in patients with high-risk resected melanoma.
    Cancer. 2026;132:e70234.
    >> Share

    December 2025

  8. Correction to "Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study".
    Cancer. 2025;131:e70188.
    >> Share

    October 2025
  9. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    >> Share

    August 2025
  10. MILHEM MM, Zakharia Y, Davar D, Buchbinder EI, et al
    Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
    Cancer. 2025;131:e70022.
    >> Share

    July 2025
  11. MENZIES AM, Salman P, Frontera OA, Pook D, et al
    Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
    Cancer. 2025;131:e35962.
    >> Share

  12. KIM Y, Doma V, Cakir U, Kuras M, et al
    Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.
    Cancer. 2025;131:e35897.
    >> Share

    June 2025
  13. NIERENGARTEN MB
    New standard of care for patients with asymptomatic brain metastases from melanoma.
    Cancer. 2025;131:e35885.
    >> Share

    May 2025
  14. CHEN MF, Postow MA
    Top advances of the year: Neoadjuvant immunotherapy in melanoma.
    Cancer. 2025;131:e35877.
    >> Share

  15. NIERENGARTEN MB
    Two-fold increased risk of melanoma in childhood cancer survivors.
    Cancer. 2025;131:e35828.
    >> Share

    January 2025
  16. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    >> Share

    December 2024
  17. DANIELSEN JT, Zachariae R, Schmidt H, Kallehauge JF, et al
    Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35683.
    >> Share

  18. LE BRUN IC, Dalle S, Mortier L, Dereure O, et al
    Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35679.
    >> Share

    November 2024
  19. DEPALO DK, Dugan MM, Naqvi SMH, Ollila DW, et al
    A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35636.
    >> Share

    September 2024
  20. LAO CD, Moon J, Ma VT, Fruehauf JP, et al
    Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587.
    >> Share

    July 2024
  21. ROZEMAN EA, Luke JJ
    The emergence of neoadjuvant immune-over BRAF therapy in melanoma.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35490.
    >> Share

    June 2024
  22. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    >> Share

  23. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    >> Share

    April 2024
  24. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    >> Share

    March 2024
  25. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    >> Share

    January 2024
  26. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    >> Share

    October 2023
  27. NIERENGARTEN MB
    First person profile: Jedd Wolchok, MD: Advances in treating metastatic melanoma can, in part, be charted by the career of Dr Wolchok, who was on the front lines of investigating immunotherapy science and developed the first immunologic agents to trea
    Cancer. 2023;129:3190-3191.
    >> Share

    September 2023
  28. EROGLU Z, Chen YA, Smalley I, Li J, et al
    Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35029.
    >> Share

    July 2023
  29. MOORADIAN MJ, Sullivan RJ
    The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Cancer. 2023;129:2117-2121.
    >> Share

  30. NIERENGARTEN MB
    Neoadjuvant immunotherapy improves outlook in high-risk melanoma.
    Cancer. 2023;129:1952.
    >> Share

    June 2023
  31. DEMKOWICZ P, Pointdujour-Lim R, Miguez S, Lee Y, et al
    Determinants of overall survival in patients with metastatic uveal melanoma.
    Cancer. 2023 Jun 29. doi: 10.1002/cncr.34927.
    >> Share

  32. MOORADIAN MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, et al
    Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Cancer. 2023;129:1904-1918.
    >> Share

    May 2023
  33. PATUZZO R, Mattavelli I, Gallino G, Galeone C, et al
    The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34824.
    >> Share

  34. GERSHENWALD JE
    Mitotic rate in primary cutaneous melanoma: Cell division matters.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34825.
    >> Share

    April 2023
  35. GALUS L, Michalak M, Lorenz M, Stoinska-Swiniarek R, et al
    Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy.
    Cancer. 2023 Apr 24. doi: 10.1002/cncr.34718.
    >> Share

    March 2023
  36. LEV-ARI S, Serzan M, Wu T, Ip A, et al
    The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34742.
    >> Share

  37. EROGLU Z, Krinshpun S, Kalashnikova E, Sudhaman S, et al
    Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Cancer. 2023 Mar 4. doi: 10.1002/cncr.34716.
    >> Share

    January 2023
  38. KLEIN O, Kee D, Nagrial A, Markman B, et al
    Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34660.
    >> Share

  39. SAHAI V, Zalupski MM
    Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?".
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34659.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016